Mark A. McElwain

424 total citations
7 papers, 294 citations indexed

About

Mark A. McElwain is a scholar working on Molecular Biology, Genetics and Cancer Research. According to data from OpenAlex, Mark A. McElwain has authored 7 papers receiving a total of 294 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 3 papers in Genetics and 2 papers in Cancer Research. Recurrent topics in Mark A. McElwain's work include Genomic variations and chromosomal abnormalities (3 papers), Cancer Genomics and Diagnostics (2 papers) and Genomics and Rare Diseases (1 paper). Mark A. McElwain is often cited by papers focused on Genomic variations and chromosomal abnormalities (3 papers), Cancer Genomics and Diagnostics (2 papers) and Genomics and Rare Diseases (1 paper). Mark A. McElwain collaborates with scholars based in United States and China. Mark A. McElwain's co-authors include Radoje Drmanac, Brock A. Peters, C. Thomas Caskey, Fan Xia, Baili Zhang, Christian P. Schaaf, Lorraine Potocki, Manuel L. Gonzalez‐Garay, Karen W. Gripp and Arthur L. Beaudet and has published in prestigious journals such as Nature Genetics, Blood and PLoS ONE.

In The Last Decade

Mark A. McElwain

6 papers receiving 290 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark A. McElwain United States 5 191 180 49 32 29 7 294
Heather R. Glatt-Deeley United States 7 244 1.3× 319 1.8× 73 1.5× 38 1.2× 10 0.3× 10 433
Bettina Lipkowitz Germany 6 168 0.9× 297 1.6× 28 0.6× 60 1.9× 17 0.6× 6 383
Paola Castronovo Italy 11 182 1.0× 237 1.3× 27 0.6× 40 1.3× 16 0.6× 21 382
Babett Heye Germany 7 206 1.1× 147 0.8× 21 0.4× 48 1.5× 17 0.6× 7 365
Hirofumi Kashii Japan 8 76 0.4× 104 0.6× 15 0.3× 56 1.8× 17 0.6× 15 245
Anne‐Claude Tabet France 14 333 1.7× 224 1.2× 79 1.6× 103 3.2× 11 0.4× 30 484
Stephen C. Collins United States 9 130 0.7× 160 0.9× 72 1.5× 52 1.6× 31 1.1× 12 333
Fabiola Ceroni United Kingdom 9 145 0.8× 125 0.7× 10 0.2× 39 1.2× 25 0.9× 14 242
Asma Al-Tawari Kuwait 6 243 1.3× 211 1.2× 162 3.3× 12 0.4× 22 0.8× 10 354
Stacie L. Taylor United States 8 197 1.0× 84 0.5× 25 0.5× 35 1.1× 4 0.1× 10 361

Countries citing papers authored by Mark A. McElwain

Since Specialization
Citations

This map shows the geographic impact of Mark A. McElwain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. McElwain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. McElwain more than expected).

Fields of papers citing papers by Mark A. McElwain

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. McElwain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. McElwain. The network helps show where Mark A. McElwain may publish in the future.

Co-authorship network of co-authors of Mark A. McElwain

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. McElwain. A scholar is included among the top collaborators of Mark A. McElwain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. McElwain. Mark A. McElwain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
McElwain, Mark A., Karen Nguyen, Devon M. Fitzgerald, et al.. (2023). Analytical Validation of a Duplex Sequencing AML Assay with a Limit of Detection Below 0.01% VAF for SNVs and Indels. Blood. 142(Supplement 1). 6020–6020.
2.
McElwain, Mark A. & Brock A. Peters. (2022). Accurate Sequencing and Haplotyping from 10 Cells Using Long Fragment Read (LFR) Technology. Methods in molecular biology. 2590. 71–84. 1 indexed citations
3.
McElwain, Mark A., Rebecca Yu Zhang, Radoje Drmanac, & Brock A. Peters. (2017). Long Fragment Read (LFR) Technology: Cost-Effective, High-Quality Genome-Wide Molecular Haplotyping. Methods in molecular biology. 1551. 191–205. 4 indexed citations
4.
Peters, Brock A., Bahram G. Kermani, Misha R. Agarwal, et al.. (2015). Detection and phasing of single base de novo mutations in biopsies from human in vitro fertilized embryos by advanced whole-genome sequencing. Genome Research. 25(3). 426–434. 37 indexed citations
5.
Schaaf, Christian P., Manuel L. Gonzalez‐Garay, Fan Xia, et al.. (2013). Truncating mutations of MAGEL2 cause Prader-Willi phenotypes and autism. Nature Genetics. 45(11). 1405–1408. 210 indexed citations
6.
McElwain, Mark A., Dennis C. Ko, Michael D. Gordon, et al.. (2011). A Suppressor/Enhancer Screen in Drosophila Reveals a Role for Wnt-Mediated Lipid Metabolism in Primordial Germ Cell Migration. PLoS ONE. 6(11). e26993–e26993. 19 indexed citations
7.
McElwain, Mark A., Susan E. Francis, Eric G. Muller, et al.. (2004). Analysis of a Spindle Pole Body Mutant Reveals a Defect in Biorientation and Illuminates Spindle Forces. Molecular Biology of the Cell. 16(1). 141–152. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026